Psychometric evaluation of an electronic Asthma Symptom Diary for young children

Valerie Williams1,1, Carla Romano2, Marci Clark3

  • 1RTI Health Solutions, Research Triangle Park, NC, USA. vwilliams@rti.org.

PubMed

Insights

The electronic Pediatric Asthma Symptom Diary (ePASD) reliably measures asthma symptoms in children aged 6-11. This digital tool is valid for assessing pediatric asthma, supporting its use in clinical trials.

Area of Science:

  • Pediatric pulmonology
  • Clinical informatics
  • Health outcomes research

Background:

  • Patient-reported outcome measures (PROMs) are crucial for reducing proxy reporting bias in pediatric asthma research.
  • The electronic Pediatric Asthma Symptom Diary (ePASD) was developed for children aged 6-11 to assess daily asthma symptoms and impacts.
  • ePASD utilizes a digital platform with multimedia elements to minimize reading skill dependency for accurate self-reporting.

Purpose of the Study:

  • To describe the psychometric properties of the electronic Pediatric Asthma Symptom Diary (ePASD).
  • To evaluate the reliability, validity, and discriminating ability of the ePASD for pediatric asthma symptom assessment.

Main Methods:

  • Ninety-one children (6-11 years) with mild to severe asthma participated.
  • Children completed the ePASD twice daily for 8 days on a provided digital device.
  • Psychometric properties including reliability, construct validity, and discriminating ability were assessed.

Main Results:

  • The ePASD demonstrated satisfactory internal consistencies (Cronbach's alpha ≥ 0.52) and test-retest reliabilities (ICC ≥ 0.60).
  • Convergent and divergent correlations supported the construct validity of ePASD scores.
  • Known-groups analyses provided evidence for the discriminating ability of ePASD items and scores.

Conclusions:

  • The ePASD is a reliable and valid tool for assessing asthma symptoms and impacts in children aged 6-11.
  • The established psychometric properties support the ePASD's use in future pediatric asthma clinical trials.
  • Further research is ongoing to evaluate the ePASD's responsiveness to treatment changes.
Abstract